March 16, 2022 | From the Trenches

A Virtual Company In A Virtual World

In December 2019, I was in London meeting with my future co-founders to discuss an asset that would eventually become the cornerstone of a virtual drug development company. At that time, Kinaset Therapeutics, Inc. as it would become, had negotiated terms to in-license an asset from a UK based company that was changing its strategy. With terms agreed and a period of exclusivity in hand, the plan was to launch a private fundraising on the heels of JP Morgan in January 2020.

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC.

March 9, 2022 | From the Trenches

Staying Human in the Age of Artificial Intelligence

No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI technology will absolutely play a key role in solving some of the biggest healthcare challenges we face today. In fact, it is already doing that by revolutionizing drug discovery, clinical research, and several other aspects of pharmaceutical R&D.

By Jonathan Montagu, CEO of HotSpot Therapeutics, and Ramy Farid, CEO of Schrodinger, as part of the From The Trenches feature of LifeSciVC.

March 3, 2022 | In the News

Atlas lands $450M fund to build fresh batch of biotechs

Atlas Venture has gathered another pot of cash for biotech creation. Less than two years after disclosing a $400 million fund, the Massachusetts-based VC shop has reeled in still more money for its next wave of new startups.

March 3, 2022 | Press Release

Atlas Venture Announces $450M Fund XIII

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its thirteenth fund, raising $450 million in an oversubscribed fundraise. With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to create and invest in a new set of biotech companies aimed at delivering impactful medicines to patients.

March 2, 2022 | From the Trenches

Going Out On A Limb: Lessons I’ve Learned Chasing My Dreams

One of the most common questions I get asked is how I got into the business side of the biotech industry, and in particular business development. My career path did not follow a predictable, straight line. I had not set out intending to become a chief business officer at a biotech company. It was a combination of the decisions I made and risks I took over the course of my varied professional experiences that led me where I am today.

By Deanna M. Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC.